127 results on '"Alcedo, Javier"'
Search Results
2. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)
3. V Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori
4. Clinical Practice Guidelines. V Spanish Consensus Conference on Helicobacter pylori infection treatment
5. Recomendaciones de la Asociación Española de Neurogastroenterología y Motilidad (ASENEM) para el reinicio de la actividad de los laboratorios de motilidad digestiva, tras el confinamiento por el estado de alarma decretado a raíz de la pandemia por COVID-19
6. Prospective comparative study between two first-line regimens for Helicobacter pylori eradication: Non-bismuth quadruple versus bismuth quadruple therapy
7. Combination of Bismuth and Standard Triple Therapy Eradicates Helicobacter pylori Infection in More than 90% of Patients
8. REVIEW DOCUMENT OF THE SPANISH ASSOCIATION OF NEUROGASTROENTEROLOGY AND MOTILITY ON THE MANAGEMENT OF OPIOID-INDUCED CONSTIPATION.
9. Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real‐world efficacy from the EoE CONNECT registry
10. Gastroenterologists’ attitudes on the detection and management of gastric premalignant conditions: results of a nationwide survey in Spain
11. Corrigendum to “Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry” [Digestive and Liver Disease Volume 55, Issue 3, March 2023, Pages 350–359]
12. Role of proton pump inhibitors dosage and duration in Helicobacter pylorieradication treatment: Results from the European Registry on H. pylorimanagement
13. Helicobacter pylori infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study
14. PAPEL DEL USO DE PROBIÓTICOS EN LA EFECTIVIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)
15. 127 - IMPACTO DEL USO DE PROBIÓTICOS EN LA SEGURIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)
16. 133 - PATRÓN DE PRESCRIPCIÓN DE PROBIÓTICOS ADYUVANTES A LA TERAPIA ERRADICADORA FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI (HP-EUREG)
17. Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report
18. Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg)
19. Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry
20. Indications and hemoglobin thresholds for red blood cell transfusion and iron replacement in adults with gastrointestinal bleeding: An algorithm proposed by gastroenterologists and patient blood management experts
21. Evaluation of a New Monoclonal Chemiluminescent Immunoassay Stool Antigen Test for the Diagnosis of Helicobacter pylori Infection: A Spanish Multicentre Study
22. Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of the EoE CONNECT Registry
23. V Spanish Consensus Conference on Helicobacter pylori infection treatment
24. Recommendations of the Spanish Association of Neurogastroenterology and Motility (ASENEM) to restart the activity of gastrointestinal motility laboratories after the state of alarm called due to the COVID-19 pandemic
25. Indications and hemoglobin thresholds for red blood cell transfusion and iron replacement in adults with gastrointestinal bleeding: An algorithm proposed by gastroenterologists and patient blood management experts
26. Outcomes of per-oral endoscopic myotomy in patients with spastic esophageal motility disorders not fulfilling Chicago Classification criteria
27. EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe
28. The Validity of the Invasive Tests for Helicobacter Pylori Diagnosis is Unequally Affected by the Consumption of Antibiotics or Pump Inhibitors. Test Performance under Real-World Conditions
29. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain
30. Guía de práctica clínica. V Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori
31. European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVID‐19 pandemic
32. V Spanish Consensus Conference on Helicobacter pylori infection treatment
33. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain
34. Gastroenterologists’ attitudes on the detection and management of gastric premalignant conditions: results of a nationwide survey in Spain
35. Trends in Barrettʼs esophagus diagnosis in Southern Europe: implications for surveillance
36. Gastroenterologists' attitudes on the detection and management of gastric premalignant conditions: results of a nationwide survey in Spain.
37. Helicobacter pylori infection does not protect against eosinophilic esophagitis: results from a large multicenter case-control study
38. Long-term results with lanreotide in patients with recurrent gastrointestinal angiodysplasias bleeding or obscure gastrointestinal bleeding. Benefits in efficacy and procedures consumption
39. CagA-positive Helicobacter pylori infection is not associated with decreased risk of Barrett's esophagus in a population with high H. pylori infection rate
40. Socioeconomic and demographic factors associated with failure in Helicobacter pylori eradication using the standard triple therapy.
41. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry.
42. PROSPECTIVE COMPARATIVE STUDY OF TWO FIRST-LINE REGIMENS FOR HELICOBACTER PYLORI ERADICATION: 14-DAYS NON-BISMUTH QUADRUPLE OPTIMIZED CONCOMITANT THERAPY VERSUS 10-DAYS BISMUTH-CONTAINING QUADRUPLE THERAPY USING A THREE-IN-ONE CAPSULE.
43. Step-Up Empiric Elimination Diet for Pediatric and Adult Eosinophilic Esophagitis: The 2-4-6 Study
44. Prospective comparative study between two first-line regimens for Helicobacter pylorieradication: Non-bismuth quadruple versus bismuth quadruple therapy
45. Preguntas comunes y respuestas razonadas sobre el síndrome del sobrecrecimiento bacteriano intestinal (SIBO)
46. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study.
47. 1119 - Step-Up Empiric Elimination Diet for Pediatric and Adult Eosinophilic Esophagitis: The 2-4-6 Study
48. Duodenosis linfocítica: estudio etiológico y formas de presentación clínica
49. Spectrum of gluten-sensitive enteropathy in patients with dysmotility-like dyspepsia
50. PAPEL DEL USO DE PROBIÓTICOS EN LA EFECTIVIDAD DE LOS TRATAMIENTOS FRENTE A HELICOBACTER PYLORI: RESULTADOS DEL REGISTRO EUROPEO SOBRE EL MANEJO DE LA INFECCIÓN POR HELICOBACTER PYLORI(HP-EUREG)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.